OncoMatch/Clinical Trials/NCT07217171
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Is NCT07217171 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including EVOLVE104 and EVOLVE104 for bladder cancer.
Treatment: EVOLVE104 · EVOLVE104 — The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Esophageal Carcinoma
Penile Carcinoma
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
documented disease progression during or post treatment with standard of care, dependent upon tumor type
Lab requirements
Blood counts
adequate organ function, as indicated by standard blood tests
Kidney function
adequate organ function, as indicated by standard blood tests
Liver function
adequate organ function, as indicated by standard blood tests
Adequate organ function, as indicated by standard blood tests
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- Yale University Cancer Center · New Haven, Connecticut
- The Winship Cancer Institute Emory University · Atlanta, Georgia
- START Midwest · Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify